Blueprint Medicines — Technical Presentation (April 2022)
27 slides from Blueprint Medicines's technical presentation, Apr 8, 2022
Slide 1: Precision that Moves
Precision that Moves Diane L. Patient with EGFR - driven lung cancer
Slide 2: Blueprint Medicines call participants
Blueprint Medicines call participants 2 Introduction and portfolio overview Kate Haviland Chief Executive Officer Initial data from the SYMPHONY trial of BLU - 945 presented at the AACR Annual Meeting 2022 David Spigel, M.D. Chief Scientific Officer Sarah Cannon Research Institute Portfolio strategy
Slide 3: Forward-looking statements
Forward - looking statements 3 This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended . The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predi
Slide 4: Blueprint Medicines is poised for growth in 2022 and beyond
Blueprint Medicines is poised for growth in 2022 and beyond * Cash, cash equivalents and investments as of December 31, 2021. 4 STRONG FINANCIAL POSITION WITH ~$1B CASH AT YEAR - END 2021* Advance our clinical - stage pipeline targeting difficult - to - treat and prevalent cancer drivers Transform t
Slide 5: Increasing tumor resistance and complexity drives disease progression
Increasing tumor resistance and complexity drives disease progression, with no approved therapies after 1L standard of care osimertinib Approximate patient numbers covering major markets – US, EU4, UK, and Japan. 1. Excludes rare mutations including exon 20 insert ions. Internal estimates adapted fr
Slide 6: Opportunities for our next-generation EGFR precision therapies
Opportunities for our next - generation EGFR precision therapies Approximate patient numbers covering major markets – US, EU4, UK, and Japan. 1. Excludes rare mutations including exon 20 insert ions. Internal estimates adapted from Ramalingam, et al. NEJM, 2020; Decision Resources Group: NSCLC Forec
Slide 7: Our portfolio of EGFR therapies are purpose-built to address medical needs
Our portfolio of EGFR therapies are purpose - built to address medical needs CS, C797S resistance mutation; Ex20in, activating exon 20 insertion mutations; LR, L858R activating mutation; TM, T790M resis tan ce mutation. 7 Not for promotional use. Effectively block the EGFR pathway Establish 2L+ SOC
Slide 8: Emerging evidence of activity in advanced EGFR-mutant NSCLC in SYMPHONY study
Emerging evidence of activity of BLU - 945 in patients with advanced EGFR - mutant NSCLC utilizing circulating tumor DNA in the Phase 1/2 SYMPHONY study American Association for Cancer Research Annual Meeting 2022 April 8, 2022 Elaine Shum, Yasir Elamin, Karen L Reckamp, Zofia Piotrowska, Julie Roto
Slide 9: Disclosures
Disclosures Dr. David Spigel, MD, Chief Scientific Officer, Sarah Cannon Research Institute • Research funding : Aeglea Biotherapeutics, Agios, Apollomics, Arcus, Arrys Therapeutics, Astellas, AstraZeneca, Bayer, BeiGene, BIND Therapeutics, BioNTech RNA Pharmaceuticals, Blueprint Medicines, Boehring
Slide 10: Combinations are needed to prevent and treat mutational heterogeneity
Combinations are needed to prevent and treat mutational heterogeneity, and prolong patient benefit in EGFR mutant NSCLC 1. Supplemental data in Soria et al NEJM 2018. Ramalingam et al NEJM 2020. 2. Leonetti, et al. British Journal of Cancer, 201 9. 1L, first - line; 2L, second - line; 3L, third - li
Slide 11: Potency and selectivity enable wide therapeutic index and broad EGFR coverage
BLU - 945 potency and selectivity enable wide therapeutic index and broad EGFR coverage, including activating L858R mutation BLU - 945’s therapeutic index enables potent inhibition of EGFR mutants compared to SOC therapies 1 BLU - 945 is active alone in combination with BLU - 701 in an osimertinib -
Slide 12: SYMPHONY first-in-human clinical trial
SYMPHONY first - in - human clinical trial of BLU - 945 a Based on Bayesian Optimal Interval escalation design (BOIN); b BID dosing will also be evaluated; c Part 1B and Phase 2 have not been initiated and are dependent on Part 1A results. ctDNA, circulating tumor DNA; DUSP6, dual specificity phosph
Slide 13: Demography and baseline characteristics
Demography and baseline characteristics a Original study protocol permitted ECOG PS of 0 – 2, but was later amended to ECOG PS of 0 – 1; b Patients with EGFR - mutant NSCLC are enrolled based on local mutation assessment of tumor biopsy or blood ctDNA with central ctDNA assessment at C1D1; c Results
Slide 14: Generally well-tolerated in the ongoing Phase 1/2 trial
BLU - 945 was generally well - tolerated in the ongoing Phase 1 trial 14 AE, adverse event; DLT, dose - limiting toxicity; MTD, maximum tolerated dose. As of the data cut - off (March 9, 2022), 33 patients have been treated with BLU - 945 at 25 – 400 mg once daily (QD) in the first 5 cohorts. Not fo
Slide 15: Exposure showed increasing coverage of activating and resistance mutations at higher doses
BLU - 945 exposure showed increasing IC 90 coverage of activating and resistance mutations at higher doses Dashed lines represent IC 90 for indicated EGFR mutants. C, Cycle; D, day; QD, once daily. As of the data cut - off (March 9, 2022), 33 patients have been tre ated with BLU - 945 at 25 – 400 mg
Slide 16: Treatment led to dose-dependent reductions in ctDNA
BLU - 945 treatment led to dose - dependent reductions in ctDNA a P atient had two different DNA mutations in C797S. Note: reductions in individual variant allele fractions as shown; therefore, pa tients with multiple mutations may be represented on both plots. All T790M and C797S allele fractions w
Slide 17: Dose-dependent anti-tumor activity, with tumor shrinkage at doses ≥200 mg QD
BLU - 945 showed dose - dependent anti - tumor activity, with tumor shrinkage reported at doses ≥200 mg QD a Patients with measurable target lesions at baseline with post - baseline scans (investigator assessed); b Data cut off, March 9, 2022; CR, complete remission; EOT, end of treatment; PD, progr
Slide 18: Patient cases: encouraging signs of clinical activity at higher doses
Patient 2 • 70 - year - old Asian female, no smoking history • Diagnosed stage IVB • Three prior therapies, achieved PRs and PD • Multiple target and non - target lesions • 200 mg QD • All detectable mutations decreased at C1D15 • 21% and 28% tumor reduction at C2D1 and C3D1, respectively Patient ca
Slide 19: Patient case: ctDNA and exposure analyses in patient treated at 50 mg
Patient case: ctDNA and exposure analyses in patient treated at 50 mg highlight polyclonal disease and potential of combination treatment QD, once daily. EOT, end of treatment. I/O, immunotherapy. As of the data cut - off (March 9, 2022), 33 patients have been treated with BLU - 945 at 25 – 400 mg o
Slide 20: Conclusions
Conclusions • In the ongoing Phase 1 trial, BLU - 945, a highly potent and selective oral EGFR inhibitor, was generally well tolerated at clinically active doses in heavily pre - treated patients with EGFRm NSCLC • Few AEs characteristic of wild - type EGFR toxicity observed at doses up to 400 mg QD
Slide 21: Acknowledgements
Acknowledgements 21 • Participating patients and families • SYMPHONY trial investigators and research coordinators • Clinical trial sites: • Colleagues at Blueprint Medicines Corporation Cedars - Sinai Medical Center, Los Angeles, CA Samsung Medical Center, Seoul, Korea Dana - Farber Cancer Institut
Slide 22: Portfolio strategy and next steps
Portfolio strategy and next steps Fouad Namouni, MD, President, R&D
Slide 23: Early dose escalation data achieve clinical proof-of-concept
Early BLU - 945 dose escalation data achieve clinical proof - of - concept 23 Dose - dependent reductions in ctDNA allele fractions for EGFR resistance mutations targeted by BLU - 945 Increasing coverage of EGFR activating and resistance mutations at higher doses, based on pharmacokinetic data Gener
Slide 24: Phase 1/2 trials to rapidly generate data in broad populations
Phase 1/2 trials to rapidly generate data in broad populations, informing development and registration strategies PLANNED INITIATION OF PHASE 1/2 SYMPHONY / HARMONY TRIAL COHORTS 1L 2L+ 2023 701 + ADC 945 + osi 701 + chemo 701 + osi Q2 2022 945 + osi 945 2H 2022 945 + ADC 701 945 + 701 945 + chemo 7
Slide 25: Phase 1/2 VELA trial of BLU-222 advancing toward clinical proof-of-concept
Phase 1/2 VELA trial of BLU - 222 advancing toward clinical proof - of - concept CCNE1, cyclin E; CDK4/6i, CDK4/6 inhibitor; ER, estrogen receptor. 25 Multiple dose cohorts* RP2D Combo with ER antagonist – ER+/HER2 - breast Combo with CDK4/6i + ER antagonist – ER+/HER2 - breast Monotherapy – CCNE1 t
Slide 26: Significant progress across our portfolio will drive near-term news flow
Significant progress across our portfolio will drive near - term news flow 26 Top - line PIONEER trial data in non - advanced SM with potential to significantly expand AYVAKIT label Multiple anticipated datasets for EGFR and CDK2 programs with potential to unlock broad patient opportunities Plan to
Slide 27: Thank You
(Sblueprint. Thank You
Blueprint Medicines — Technical Presentation (April 2022) on 6ix